Development of Pyrazolo[3,4- d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme

Greco, Chiara; Taresco, Vincenzo; Pearce, Amanda K.; Vasey, Catherine E.; Smith, Stuart; Rahman, Ruman; Alexander, Cameron; Cavanagh, Robert J.; Musumeci, Francesca; Schenone, Silvia

doi:10.1021/acsmedchemlett.9b00530

All Outputs (8)

Biomedical engineering approaches to enhance therapeutic delivery for malignant glioma (2020)
Journal Article

© 2020 We review the challenges of next-generation therapeutics for both systemic and localised delivery to brain tumours and discuss how recent engineering advances may be used to enhance brain penetration of systemic delivery therapies. The unmet c... Read More about Biomedical engineering approaches to enhance therapeutic delivery for malignant glioma.

Ion channels as therapeutic targets in high grade gliomas (2020)
Journal Article

Glioblastoma multiforme (GBM) is a lethal brain cancer with an average survival of 14-15 months with maximal treatment. High grade gliomas (HGG) form a leading cause of CNS cancer-related death in children and adults due to the aggressive nature of t... Read More about Ion channels as therapeutic targets in high grade gliomas.

Ion channels as therapeutic targets in high grade gliomas (2020)
Journal Article

Abstract: Glioblastoma multiforme (GBM) is a lethal brain cancer with an average survival of 14-15 months with maximal treatment. High grade gliomas (HGG) form a leading cause of CNS cancer-related death in children and adults due to the aggressive n... Read More about Ion channels as therapeutic targets in high grade gliomas.

Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours (2020)
Journal Article

Glioblastoma is a malignant brain tumour with a median survival of 14.6 months from diagnosis. Despite maximal surgical resection and concurrent chemoradiotherapy, reoccurrence is inevitable. To try combating the disease at a stage of low residual tu... Read More about Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours.

Impact of COVID-19 Pandemic on Surgical Neuro-oncology Multi-Disciplinary Team Decision Making – A National Survey (COVID-CNSMDT Study) (2020)
Journal Article

Objectives Pressures on healthcare systems due to COVID-19 has impacted patients without COVID-19 with surgery disproportionally affected. This study aims to understand the impact on the initial management of patients with brain tumours by measuring... Read More about Impact of COVID-19 Pandemic on Surgical Neuro-oncology Multi-Disciplinary Team Decision Making – A National Survey (COVID-CNSMDT Study).

Metabolism based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential (2020)
Journal Article

Background Glioblastoma (GBM) is a highly aggressive brain tumor with rapid subclonal diversification, harboring molecular abnormalities that vary temporo-spatially, a contributor to therapy resistance. Fluorescence guided neurosurgical resection ut... Read More about Metabolism based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential.

Thioredoxin system protein expression is associated with poor clinical outcome in adult and paediatric gliomas and medulloblastomas (2020)
Journal Article

The thioredoxin (Trx) system is an important enzyme family that regulates cellular redox homeostasis. Protein expression of Trx system family members has been assessed in various cancers and linked to various clinicopathological variables, disease pr... Read More about Thioredoxin system protein expression is associated with poor clinical outcome in adult and paediatric gliomas and medulloblastomas.

Development of Pyrazolo[3,4- d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme (2020)
Journal Article

Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor. Residual cells at the tumor margin are responsible for up to 85% of GBM recurrences after standard treatment. Despite this evidence, the identification of compounds active on t... Read More about Development of Pyrazolo[3,4- d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme.